Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q2
Sell
-8,496
Closed -$347K 122
2023
Q1
$347K Sell
8,496
-851
-9% -$36.8K 0.02% 82
2022
Q4
$478K Buy
9,347
+641
+7% +$30.7K 0.03% 27
2022
Q3
$380K Sell
8,706
-19,717
-69% -$958K 0.03% 64
2022
Q2
$1.49M Hold
28,423
0.1% 39
2022
Q1
$1.47M Hold
28,423
0.08% 47
2021
Q4
$1.68M Sell
28,423
-6,567
-19% -$325K 0.09% 14
2021
Q3
$1.5M Buy
+34,990
New +$1.55M 0.09% 89
2020
Q4
Sell
-16,105
Closed -$561K 189
2020
Q3
$561K Buy
16,105
+2,419
+18% +$84.8K 0.05% 91
2020
Q2
$425K Sell
13,686
-1,790
-12% -$60.8K 0.03% 141
2020
Q1
$479K Buy
15,476
+959
+7% +$32.7K 0.04% 25
2019
Q4
$540K Buy
14,517
+763
+6% +$27.2K 0.04% 59
2019
Q3
$469K Buy
13,754
+1,814
+15% +$66K 0.04% 110
2019
Q2
$490K Buy
+11,940
New +$474K 0.05% 119
2019
Q1
Sell
-13,820
Closed -$573K 159
2018
Q4
$573K Hold
13,820
0.06% 20
2018
Q3
$578K Sell
13,820
-903
-6% -$34.8K 0.06% 23
2018
Q2
$507K Buy
14,723
+8,657
+143% +$296K 0.06% 72
2018
Q1
$204K Buy
6,066
+423
+7% +$14.5K 0.03% 84
2017
Q4
$194K Hold
5,643
0.02% 143
2017
Q3
$191K Buy
+5,643
New +$181K 0.03% 58
2015
Q1
Sell
-5,100
Closed -$151K 186
2014
Q4
$151K Hold
5,100
0.02% 80
2014
Q3
$143K Buy
+5,100
New +$143K 0.02% 46

Other funds holding PFE

SRB Corp's PFE Position: Q2 2023 in Review

SRB Corp sold out of Pfizer (PFE) in Q2 2023, closing a stake of 8,496 shares — an estimated $347K sold.

SRB Corp first reported a position in PFE in Q3 2014 and held it in 21 quarters. The position peaked at $1.68M in Q4 2021. 3,041 funds tracked by Wall St. Rank hold PFE as of Q2 2023.

  • SRB Corp reported no remaining Pfizer position as of Q2 2023 after selling out during the quarter.
  • SRB Corp sold 8,496 Pfizer shares in Q2 2023, an estimated $347K.
  • SRB Corp first reported a position in Pfizer in Q3 2014 and held it in 21 quarters.
  • SRB Corp's Pfizer position peaked at $1.68M in Q4 2021.
  • 3,041 funds tracked by Wall St. Rank held Pfizer as of Q2 2023.

Based on SRB Corp's 13F filing for Q2 2023, filed 14 Aug 2023.